In this, the final article in the series on carotenoids, Susan Taylor In fact, the ATBC study from Finland reported a negative effect of beta-carotene supplementation with respect to the incidence of lung cancer in smokers.
Since then, two other major studies in the United States have shown either no effect or a negative effect on chronic diseases.
In concluding, the author supports an increased consumption of fruits and vegetables and the avoidance of supplementary beta-carotene for smokers. Her recommendations are timely. CARET is a multicenter lung cancer prevention trial of supplemental beta-carotene (30 mg/day) plus retinol (25,000 lU/day) vs. placebo in asbestos workers and smokers. According to Dr. Gilbert Omenn, the lead investigator of CARET, the intervention was stopped early because interim analyses of the data indicated that should the trial have continued for its planned duration, it is highly unlikely that the intervention would have been found to be beneficial, given the results as of late 1995. Furthermore, the interim results indicated that the supplemented group was develop-
OVERVIEW OF EPIDEMIOLOGIC STUDIES OF CAROTENOIDS
CARET, Carotene and Retinol Efficacy Trial; EPP, erythropoietic protophorphyria; IHD, ischemic heart disease. were also released at the same press conference.
Dr. Charles Hennekens, lead investigator of the Physicians' Health Study, announced that there was no significant effect-positive or negative-of 12 years of supplementation of beta-carotene (50 mg every other day) on cancer or cardiovascular disease. The apparent lack of an effect of long-term supplementation of beta-carotene on lung cancer incidence in this cohort is noteworthy.
Nonetheless, these negative results should not be overinterpreted as only 11% of the cohort were current smokers at entry.
In contrast to these findings are results of an esophageal and gastric cancer prevention trial in China (discussed below). This trial had limited statistical power for lung cancer with only 31 total lung cancer deaths (19). However, the relative risk of death from lung cancer was 0.55 (95% CIO.26-1.14)
among those receiving the combination of beta-carotene, alpha-tocopherol, and selenium. The smoking prevalence, including individuals who had ever smoked cigarettes for6 or more months, was 30% in this study population. Possible reasons for the discrepant results of the CARET, ATBC, Physicians ' and Chinese trials are discussed below (see "Carotenoids and Cancer: Overall Assessment").
Oral, pharynx, and larynx
As reviewed elsewhere, epidemiologic studies of diet and serum, studies using the hamster buccal pouch model, and human intervention trials using intermediate markers of oral carcinogenesis strongly suggest that beta-carotene plays a protective role in the prevention of cancers of the oral cavity, pharynx, and larynx (20). The etiology of these cancers, also known as head and neck cancers, is thought to be multifactorial. Well-characterized risk factors include tobacco and alcohol exposures. A recent case-control study of oral cancer from northern Italy attempted to estimate the relative contribution of beta-carotene intake, alcohol, and tobacco exposures to this cancer (21). In this study, smoking accounted for 81-87% of oral cancer in males and 42-47% in females; alcohol explained about 60% of male cases vs. 15% of female cases, and low beta-carotene intake accounted for 25% of cases in males vs. 17% in females. Even though this study provides new information regarding the relative importance of diet in the etiology of these cancers, the calculated attributable risk for low beta-carotene intake should be interpreted cautiously, as the beta-carotene index was derived from a few selected indicator foods rather than from an analysis of the whole diet. Thus, some misclassification of intake is likely.
Another Table 2 . Although many of these trials were not placebo-controlled, and were thus subject to bias, the consistency of the results strongly suggests a role for supplemental beta-carotene in the prevention of oral cancers. Based on these results, three trials involving beta-carotene and head and neck cancer prevention were initiated: one in the U.S. (23) 
CAROTENOIDS AND CANCER: OVERALL ASSESSMENT
Taking the epidemiological evidence regarding carotenoids and cancer as a whole, the consistent protective effects found in the observational studies are strikingly at odds with the findings of the large supplement intervention trials, only one of which showed a decrease in cancer incidence with supplementation (26), three of which showed essentially no effect (28, 37, Physicians' Health Study), and two of which showed an increase in cancer incidence (17, CARET CARET, who had taken daily supplements of 30 mg betacarotene and 25,000 IU retinol for up to 6 years. A small but statistically significant increase in serum aipha-tocopherol levels was observed in the supplemented subjects in this very robust study. There was no evidence of a decrease in vitamin E levels in any of the subgroups examined. These and other reports do not support an adverse effect of long-term supplemental beta-carotene on vitamin E levels in blood, although data are lacking regarding effects on tissue stores of vitamin E.
Adverse effects of supplemental beta-carotene on plasma levels of other carotenoids also have been considered. Micozzi and colleagues (43) showed that supplementation with either 12 or 30 mg beta-carotene/day for 6 wk reduced plasma lutein levels relative to placebo (five subjects/group).
Kostic and colleagues (44) gave single oral doses of lutein with and without beta-carotene (both 0.5 p.mollkg body weight) and showed that when both carotenoids were administered together, the mean area under-the-curve for plasma lutein was reduced significantly. In contrast to these relatively small, short-term studies, Wahlqvist and colleagues (45) reported that supplementation of 20 mg beta-carotene/day for 24 months not only elevated plasma alpha-carotene levels (211% in men and 166% in women), but also lycopene levels (176% in men; lycopene levels were elevated nonsignificantly in women; total n224).
Lutein/zeaxanthin levels were unaffected by beta-carotene supplementation.
Omenn and colleagues (46) effects. This analysis is not straightforward, however, in that the bioavailability of a given oral dose of beta-carotene could be affected by coadministration of other agents such as retinol, may differ with different formulations, and is affected by dietary variables such as fat intake. These and other factors may account for the fact that populations appear to differ in their plasma responses to supplemental beta-carotene.
For example, median serum beta-carotene levels in the participants receiving 20 mg beta-carotene/day (Hoffmann-LaRoche product) in the Finnish trial rose from 0.18 mg/i at baseline to 3.0 mg/l at 3 years (17). In contrast, median plasma beta-carotene levels in the participants receiving 50 mg beta-carotene/day in the skin cancer prevention trial (BASF product) rose from 0.18 mg/i at baseline to only 1.7 mg/l at 3 years (37). In our experience, median plasma beta-carotene levels of patients with a prior head or neck malignancy, who received the same 50 mg beta-carotene/day supplement used by Greenberg and colleagues, rose from 0.18 mg/l at baseline to approximately 1.2 mg/lat 3 and 12 months (unpublished data). Thus, an analysis of dose-response effects should consider blood and tissue levels of beta-carotene, as well as oral dose levels, due to wide discrepancies in physiologic responses to a given oral dose.
The currently available data indicate that supplemental beta-carotene is unlikely to be beneficial in reducing the major cancers occurring in westernized populations. These findings, however, may not extend to less common malignancies. In this regard, supplemental beta-carotene has been shown to reduce precancerous lesions of the oral cavity (Table  2 ) and cervix (35), but not of the lung (15). Thus, the possible efficacy of beta-carotene and othercarotenoids in the prevention of oral and cervical neoplasia should be explored further.
OTHER HEALTH EFFECTS OF CAROTENOIDS

Photosensitivity disorders
Carotenoids, including beta-carotene and to a lesser extent canthaxanthin, have been used successfully to treat certain photosensitivity diseases for more than 25 years. This clinical application derived from the recognition that carotenoids protect photosynthetic bacteria, algae, and green plants against photosensitization (50) . As reviewed elsewhere (50) , many studies have demonstrated that the majority of patients with the genetic disease erythropoietic protoporphyria (EPP) benefit from high-dose supplementation of beta-carotene and/or canthaxanthin. Recommended beta-carotene doses for adults with EPP are approximately 180 mg/day, substantially higher than the doses investigated for cancer prevention purposes (15-50 mg/day). Despite these relatively high doses, some patients with EPP do not respond to carotenoid therapy, due either to poor absorption of the carotenoids or to markedly elevated blood porphyrin levels.
No serious side effects from high-dose beta-carotene supplements have been reported in EPP patients, and no long-term toxicity has been observed (50) . High-dose supplementation with canthaxanthin, however, has been shown to produce deposition of pigmented granules in the retinas of some patients, with occasional effects on night vision (51) . Because many patients with EPP have been maintained on high doses of beta-carotene for a relatively long time, a retrospective cohort analysis of these patients to assess the incidence of chronic disease would be instructive.
The problem with this approach is difficulty in assembling a suitable control group (EPP patients without carotenoid therapy).
Cardiovascular diseases
Epidemiologic studies, including descriptive, cohort, and case control studies, suggest that carotenoidand/or betacarotene-rich diets may prevent cardiovascular disease, as reviewed elsewhere (52) . For example, Gey and colleagues (53) reported data from the Vitamin Substudy of the WHO/MONICA Project, in which plasma was obtained from approximately 100 healthy males from each of 16 study sites within Europe for antioxidant nutrient analyses. Median antioxidant nutrient levels were then compared with concurrent age-specific ischemic heart disease (IHD) mortality in the 16 study populations.
Results showed a striking inverse correlation of IHD mortality with plasma vitamin E levels (r20.63). A similar comparison between median plasma beta-carotene levels and IHD mortality revealed no association when considering all 16 study sites (r20.04).
However, a reasonably strong inverse association was evident (r20.50) when three study sites, all apparent outliers (and all Finnish sites), were excluded from the analysis.
Gey and colleagues (53) 
